Abstract
Objective
Currently, there are two categories of epidermal growth factor receptor (EGFR) antagonists, small molecule antagonists and anti-EGFR antibodies. In the current study, we developed a new EGFR antagonist employing the anti-idiotypic antibodies strategy.
Results
First, using EGF as an antigen, through a series of immunological protocols and hybridoma technology, we obtained an anti-idiotypic antibody against EGF receptor-binding epitopes. On this basis, we screened and characterized the anti-idiotype antibodies against EGFR through competitive ELISA, co-localization analysis, competitive receptor binding analysis, and immunofluorescence. Finally, an internal image anti-idiotype antibody called FG8 was successfully prepared. Experiment result shows that FG8 inhibits EGFR-mediated signaling pathways in vitro. Additionally, FG8 inhibits liver tumor cell proliferation as well as induces tumor cell apoptosis.
Conclusions
The present study suggests that FG8 is a potential therapeutic agent for liver cancer. In addition, this study provides a novel method for the preparation of EGFR antagonists.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- EGF:
-
Epidermal growth factors
- EGFR:
-
Epidermal growth factor receptor
- STAT3:
-
Signal transducers and activators of transcription 3
- AKT:
-
Protein kinase B
References
Blobel CP (2005) ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 6:32–43. https://doi.org/10.1038/nrm1548
Burotto M, Manasanch EE, Wilkerson J, Fojo T (2015) Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 20:400–403. https://doi.org/10.1634/theoncologist.2014-0154
Hama T, Yuza Y, Saito Y (2009) Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 14:1–9. https://doi.org/10.1634/theoncologist.2009-0058
Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H (2007) Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 120:781–787. https://doi.org/10.1002/ijc.22370
Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Haggstrom D (2015) AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer. New Engl J Med 372:1689–1699. https://doi.org/10.1056/NEJMoa1411817
Jerne NK (1974) (1974) Towards a network theory of the immune system. Ann Immunol. 125:373–375. https://doi.org/10.1371/journal.pone.0065173
Kazandjian D, Blumenthal GM, Yuan W, He K, Keegan P, Pazdur R (2016) FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation–positive non–small cell lung cancer. Clin Cancer Res. 22:1307–1312. https://doi.org/10.1158/1078-0432.CCR-15-2266
Kohler H, Pashov A, Kieber-Emmons T (2019) The promise of anti-idiotype revisited. Front Immuno 10:808–902. https://doi.org/10.3389/fimmu.2019.00808
Lan H, Zheng X, Khan MA, Li S (2015) Anti-idiotypic antibody: A new strategy for the development of a growth hormone receptor antagonist. Int J Biochem Cell B 68:101–108. https://doi.org/10.1016/j.biocel.2015.09.004
Lan H, Hong P, Li R, Suo L, Anshan S, Li S, Zheng X (2017) Internal image anti-idiotypic antibody: a new strategy for the development a new category of prolactin receptor (PRLR) antagonist. Mole Immunol 87:86–93. https://doi.org/10.1016/j.molimm.2017.04.006
Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134. https://doi.org/10.1016/j.cell.2010.06.011
Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL (2009) Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28:3801–3813. https://doi.org/10.1038/onc.2009.234
Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Salomon DS (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2–16. https://doi.org/10.1016/j.gene.2005.10.018
Ren S, Kuang P, Zheng L, Su C, Li J, Li B, Hu Q (2012) Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys 64:155–160. https://doi.org/10.1007/s12013-012-9384-8
Viloria-Petit AM, Kerbel RS (2004) Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys 58:914–926. https://doi.org/10.1016/j.ijrobp.2003.09.091
Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, Rosmorduc O (2005) Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41:307–314. https://doi.org/10.1002/hep.20538
Schneider MR, Wolf E (2009) the epidermal growth factor receptor ligands at a glance. J Cell Physiol 218:460–466. https://doi.org/10.1002/jcp.21635
Stanova AK, Ryabkova VA, Utekhin SV, Shoenfeld VJ, Churilov LP, Shoenfeld Y (2020) Anti-idiotypic agonistic antibodies: candidates for the role of universal remedy. Antibodies 9:19. https://doi.org/10.3390/antib9020019
Sudhagar S, Sathya S, Anuradha R, Gokulapriya G, Geetharani Y, Lakshmi BS (2018) Inhibition of epidermal growth factor receptor by ferulic acid and 4-vinylguaiacol in human breast cancer cells. Biotechnol let 40:257–262. https://doi.org/10.1007/s10529-017-2475-2
Wang S, Song Y, Yan F, Liu D (2016) Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. Front Med 10:383–388. https://doi.org/10.1007/s11684-016-0488-1
Yarden Y (2001) The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37:3–8. https://doi.org/10.1016/s0959-8049(01)00230-1
Acknowledgements
Thanks to Li Qin for her technical support.
Supporting information
Supplementary Fig.1–Fig.4
Funding
This work was supported by Natural Science Foundation of Xinjiang Uygur Autonomous Region (2019D01C312).
Author information
Authors and Affiliations
Contributions
AR and WYR contributed to the design of the project. WY, HFP and ZHL carried out experiments. ZYQ and WYR analyzed the data, AR and WYR wrote the draft. All author review the MS.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Wang, Y., He, F., Zhang, H. et al. Preparation and identification of an anti-idiotypic antibody antagonist (FG8) for EGFR that shows potential activity against liver cancer cells. Biotechnol Lett 43, 369–382 (2021). https://doi.org/10.1007/s10529-020-03017-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10529-020-03017-6